MQS Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

MQS Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-12,982	Closed	-$98.5K	–	420
2025 Q3	$98.5K	Buy	+12,982	New	+$108K	0.06%	399

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

MQS Management's BCRX Position: Q4 2025 in Review

MQS Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 12,982 shares — an estimated $98.5K sold.

MQS Management first reported a position in BCRX in Q3 2025 and held it in 1 quarter. The position peaked at $98.5K in Q3 2025. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

MQS Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
MQS Management sold 12,982 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $98.5K.
MQS Management first reported a position in BioCryst Pharmaceuticals in Q3 2025 and held it in 1 quarter.
MQS Management's BioCryst Pharmaceuticals position peaked at $98.5K in Q3 2025.
272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on MQS Management's 13F filing for Q4 2025, filed 9 Feb 2026.